Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
petosemtamab (MCLA-158)
i
Other names:
MCLA-158, MCLA 158, MCLA158, LGR5 x EGFR Biclonics, Peto
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(2)
News
Trials
Company:
Merus
Drug class:
EGFR antagonist, LGR5 inhibitor
Related drugs:
‹
CKD-702 (6)
SCT200 (4)
CPGJ-602 (3)
rezivertinib (2)
BTG-002814 (0)
cetuximab biosimilar (CDP-1) (0)
KL 140 (cetuximab biosimilar) (0)
CKD-702 (6)
SCT200 (4)
CPGJ-602 (3)
rezivertinib (2)
BTG-002814 (0)
cetuximab biosimilar (CDP-1) (0)
KL 140 (cetuximab biosimilar) (0)
›
Associations
(2)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Squamous Cell Carcinoma of Head and Neck
No biomarker
Squamous Cell Carcinoma of Head and Neck
MCLA-158
Sensitive: B - Late Trials
MCLA-158
Sensitive
:
B
MCLA-158
Sensitive: B - Late Trials
MCLA-158
Sensitive
:
B
KRAS mutation
Colorectal Cancer
KRAS mutation
Colorectal Cancer
MCLA-158
Sensitive: D – Preclinical
MCLA-158
Sensitive
:
D
MCLA-158
Sensitive: D – Preclinical
MCLA-158
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login